Li Watsek Analyst PerformanceBiotech Analyst at Cantor FitzgeraldLi Watsek is a stock analyst at Cantor Fitzgerald in the medical sector, covering 13 publicly traded companies. Over the past year, Li Watsek has issued 15 stock ratings, including buy and hold recommendations. While full access to Li Watsek's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Li Watsek's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings23 Last 4 YearsBuy Recommendations95.65% 22 Buy RatingsCompanies Covered13 Unique Companies Ratings Distribution23RatingsDistribution of strong buy, buy, hold, and sell ratings by Li Watsek.RatingPercentageCount Strong Buy0.0%0 ratings Buy95.7%22 ratings Hold4.3%1 ratings Sell0.0%0 ratingsOut of 23 total stock ratings issued by Li Watsek at Cantor Fitzgerald, the majority (95.7%) have been Buy recommendations, followed by 4.3% Hold.Best & Worst CallsBest Call000.0%ASNDFeb 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%ACRVJan 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ13 companiesLi Watsek, an analyst at Cantor Fitzgerald, currently covers 13 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical13 companies100.0%Li Watsek of Cantor Fitzgerald specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies76.9%MED - DRUGS3 companies23.1% Li Watsek's Ratings History at Cantor Fitzgerald Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsREPLReplimune Group4/13/2026Downgrade$1.59Hold$0.0000.00% ROICMPXCompass Therapeutics3/12/2026Reiterated Rating$5.28Overweight$0.0000.00% ROIASNDAscendis Pharma A/S3/2/2026Reiterated Rating$236.07$300.00Overweight$0.0000.00% ROIZLABZai Lab2/27/2026Lower Price Target$19.14$37.00Overweight$0.0000.00% ROITYRATyra Biosciences2/24/2026Initiated Coverage$33.30Overweight$0.0000.00% ROIIDYAIDEAYA Biosciences2/18/2026Reiterated Rating$31.09Overweight$0.0000.00% ROIAVBPArriVent BioPharma12/22/2025Initiated Coverage$22.40Overweight$0.0000.00% ROICMPXCompass Therapeutics12/3/2025Initiated Coverage$5.22Overweight$0.0000.00% ROIASNDAscendis Pharma A/S11/26/2025Reiterated Rating$206.65Overweight$0.0000.00% ROIASNDAscendis Pharma A/S10/13/2025Boost Price Target$209.55$254.00Overweight$0.0000.00% ROICNTXContext Therapeutics10/2/2025Initiated Coverage$0.97Overweight$0.0000.00% ROIIDYAIDEAYA Biosciences9/9/2025Reiterated Rating$23.39Overweight$0.0000.00% ROIASNDAscendis Pharma A/S8/8/2025Boost Price Target$183.27$203.00Overweight$0.0000.00% ROIREPLReplimune Group7/30/2025Upgrade$7.53Overweight$0.0000.00% ROIREPLReplimune Group6/20/2025Initiated Coverage$9.49Overweight$0.0000.00% ROIASNDAscendis Pharma A/S5/12/2025Reiterated Rating$155.13$200.00Overweight$000.0000.00% ROITARAProtara Therapeutics3/14/2025Initiated Coverage$4.02Overweight$0.0000.00% ROIASNDAscendis Pharma A/S2/25/2025Boost Price Target$152.43$200.00Overweight$000.0000.00% ROIASNDAscendis Pharma A/S2/11/2025Reiterated Rating$118.94$170.00Overweight$000.0000.00% ROIARVNArvinas2/7/2025Reiterated Rating$19.25Overweight$00.0000.00% ROIACRVAcrivon Therapeutics1/31/2025Initiated Coverage$6.12Overweight$0.0000.00% ROIALXOALX Oncology1/24/2025Reiterated Rating$1.50Overweight$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageMorgan StanleyJefferies Financial GroupStifel NicolausOppenheimerBerenberg BankRoth MkmWall Street ZenUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.The Goldman Sachs GroupTD Cowen Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
